Science|Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing
https://www.nytimes.com/2026/11/17/science/fearing-chinese-rivals-us-biotech-adopts-a-new-norm-share-nothing.html
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.
Concerns that well-funded Chinese companies will swoop in to grab new ideas for their own drug development are shaping an industry unaccustomed to such secrecy.

By Gina Kolata
Gina Kolata spoke to 18 biotech executives and investors and read testimonies and reports to Congress on the China challenge.
Nov. 17, 2026, 5:01 a.m. ET
It used to be that companies and scientists with ideas for new drugs couldn’t wait to announce their discoveries at meetings, in preprints and on their websites.
That is changing.
Researchers at the biotechnology firm Alnylam Pharmaceuticals have an unwritten policy: Do not reveal early-stage studies or discuss unpublished data, according to its founding chief executive, Dr. Christoph Westphal.
Jacob Becraft of Strand Therapeutics delays filing for patents to keep his company’s discoveries secret. And he is careful about disclosing his company’s intellectual property and confidential material, even to investors.
Alexis Borisy, a co-founder of Curie.Bio, which helps early-stage biotechs, says he tells scientists to “go dark” — don’t publish, don’t present posters at meetings, don’t even go to meetings.
The reason for this guarded stance? Fears that Chinese companies will seize on the biotechs’ discoveries and quickly beat them to market with the U.S. firms’ own inventions or with slightly altered versions that dilute market exclusivity.
“This is the world we’re in now,” Mr. Borisy said. Meetings are where scientists discuss new ideas. Publication is the lifeblood of science. But now, being too open too soon has become too risky, he and others said.
.png)




English (US) ·